Skip to main content

Otiprio News

Otonomy Announces FDA Approval of Otiprio (ciprofloxacin otic suspension) for Acute Otitis Externa

SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) – Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...

FDA Approves Otiprio (ciprofloxacin otic suspension) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery

SAN DIEGO, Dec. 11, 2015 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Otiprio patient information at Drugs.com